Inventiva to Participate in the Jefferies Global Healthcare Conference in Early June 2026
Inventiva announces that its CEO, Andrew Obenshain, will participate in the 2026 Jefferies Global Healthcare Conference, which will take place from June 2 to June 4, 2026, in New York. The biopharmaceutical company, specializing in the development of oral therapies for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), will present its portfolio and research activities.
Andrew Obenshain, CEO of Inventiva, will speak on Wednesday, June 3, 2026, from 5:30 PM to 6:00 PM Eastern Time in New York. Besides this formal presentation, Inventiva's management will participate in individual meetings with investors and analysts throughout the conference.
Focus on MASH and Lanifibranor
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Inventiva is developing small molecules administered orally for the treatment of patients with MASH, a chronic and progressive liver disease. The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical study dedicated to adult patients affected by this condition.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -100 %
Net income: -69,5 millions d'euros
Free cash flow: -48,7 millions d'euros
Risks mentioned
La trésorerie actuelle ne couvre pas les besoins opérationnels des 12 prochains mois.
Horizon de trésorerie limité à la fin du deuxième trimestre 2027 sans financements additionnels.
Aucun chiffre d'affaires enregistré au premier semestre 2026, contre 4,5 M€ un an plus tôt.
Opportunities identified
Offre Equity de 103 M€ et Opération de Financement de 75 M€ annoncées le 2 juin 2026.
Tranche C de l'Opération de Financement pouvant apporter jusqu'à 20,0 M€.
Exercice des warrants Tranche 3 pouvant générer jusqu'à 116,0 M€.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
